Pfizer to Acquire Private RSV Antiviral Maker: Pfizer announced a definitive agreement to acquire a private biotech, ReViral, which is developing therapeutics for respiratory syncytial virus (RSV) for a total consideration of up to $525 million. The purchase consideration includes upfront and development milestones. The acquisition will strengthen Pfizer's innovative anti-infective pipeline. ReViral has some promising RSV candidates in its portfolio, including sisunatovir, an oral therapy that has significantly reduced viral load in a phase II RSV human challenge study in healthy adults while also being evaluated in a phase II study in infants.